EHS
EHS

FSD Pharma Responds to Therapix Termination of Binding LOI




TORONTO–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/FSDDF?src=hash" target="_blank"gt;#FSDDFlt;/agt;–FSD Pharma Inc. (“FSD Pharma” or “FSD”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) in response to Therapix Biosciences’ termination of the company’s binding letter of intent (LOI) to be acquired by FSD Pharma, Dr. Raza Bokhari, Executive Co-Chairman of the Board of FSD Pharma, released the following statement: “While we are disappointed that Therapix Biosciences has given notice to terminate, we determined through the course of our negotiations and due diligence that a rese

Source link

EHS
Back to top button